Live Breaking News & Updates on Clinical Laboratory Medicine
Stay updated with breaking news from Clinical laboratory medicine. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The enticing prospect – and proven worth – of dually agonizing the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors gained more evidence in a big way from Viking Therapeutics Inc. with VK-2735 in a phase II weight loss study. Shares of San Diego-based Viking Therapeutics Inc. (NASDAQ:VKTX) closed Feb. 27 at $85.05, up $46.57, or 121%, as investors learned that the drug achieved the primary and all secondary endpoints in the phase II study called Venture, with significant body-weight drops at all doses compared to placebo. ....
SocietyBreast cancer, a pervasive global health concern, is increasingly making its presence felt among young women in the subcontinent. While traditionally perceived as a disease affecting older age groups, recent trends point to a disturbing rise. ....
A breakthrough new drug to treat brain disease is always welcome news. Last summer, the performance of the drugs donanemab and lecanemab in clinical trials. ....